BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Dash P, Mohapatra S, Ghosh S, Nayak B. A Scoping Insight on Potential Prophylactics, Vaccines and Therapeutic Weaponry for the Ongoing Novel Coronavirus (COVID-19) Pandemic- A Comprehensive Review. Front Pharmacol 2020;11:590154. [PMID: 33815095 DOI: 10.3389/fphar.2020.590154] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Abusalah MAH, Khalifa M, Al-hatamleh MAI, Jarrar M, Mohamud R, Chan YY. Nucleic Acid-Based COVID-19 Therapy Targeting Cytokine Storms: Strategies to Quell the Storm. JPM 2022;12:386. [DOI: 10.3390/jpm12030386] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
2 He X, Zeng XX. Immunotherapy and CRISPR Cas Systems: Potential Cure of COVID-19? DDDT 2022;Volume 16:951-972. [DOI: 10.2147/dddt.s347297] [Reference Citation Analysis]
3 Das S, Kar SS, Samanta S, Banerjee J, Giri B, Dash SK. Immunogenic and reactogenic efficacy of Covaxin and Covishield: a comparative review. Immunol Res 2022. [PMID: 35192185 DOI: 10.1007/s12026-022-09265-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
4 Shuai Q, Zhu F, Zhao M, Yan Y. mRNA delivery via non-viral carriers for biomedical applications. Int J Pharm 2021;607:121020. [PMID: 34416327 DOI: 10.1016/j.ijpharm.2021.121020] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
5 Saleem A, Akhtar MF, Haris M, Abdel-Daim MM. Recent updates on immunological, pharmacological, and alternative approaches to combat COVID-19. Inflammopharmacology 2021. [PMID: 34331179 DOI: 10.1007/s10787-021-00850-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
6 Zanella I, Zizioli D, Castelli F, Quiros-Roldan E. Tenofovir, Another Inexpensive, Well-Known and Widely Available Old Drug Repurposed for SARS-COV-2 Infection. Pharmaceuticals (Basel) 2021;14:454. [PMID: 34064831 DOI: 10.3390/ph14050454] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 19.0] [Reference Citation Analysis]